Moderna also announced Thursday it is in Phase 2 of a study to test the vaccine on children as young as 6 months old. It’s also in Phase 3 of a study to test the vaccine on adults who have undergone kidney or liver transplants.
Additionally, Moderna said initial Phase 2 study data shows a 50-microgram booster of its vaccine increases antibody responses against COVID-19 and two variants which were first identified in South Africa and Brazil.
Moderna and Pfizer require two doses for their vaccines. Johnson & Johnson requires one. No other vaccines have been authorized in the U.S. AstraZeneca said last week that it intends to seek U.S. authorization for its COVID-19 vaccine in the “coming weeks,” acknowledging a delay in the much-anticipated filing that had been expected by mid-April.
The Associated Press contributed to this report.